Develops and manufactures diagnostic products for women's health. Offers medical imaging systems, including mammography and ultrasound. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
This is an established company with proven profits.
An average decline of 8% a year over the last 4 years — the most striking risk in this picture.
The gap is $424.1M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 30× for every dollar of annual profit — around what a business like this usually costs.
Analysts' average target sits 4% above today's price.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 4 years, sales fell about 8% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 4/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.